以前に治療された固形腫瘍を持つ成人におけるASP3082の研究
KRAS G12D変異を伴う局所進行性または転移性固形腫瘍悪性腫瘍の治療歴のある参加者におけるASP3082の第1相試験
This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D.
This study will be in 2 parts.
In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2.
In Part 2, ASP3082 will be given in by itself, or in combination with the other study treatments.
Study treatments will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. They will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Astellas Pharma Global Development, Inc.
- 電話番号:800-888-7704
- メール:astellas.registration@astellas.com
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope National Medical Center
-
Santa Monica、California、アメリカ、90404
- 募集
- UCLA Santa Monica Hematology Oncology
-
-
Colorado
-
Denver、Colorado、アメリカ、80218
- 募集
- Denver HealthONE Drug Development Unit
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520-8028
- 募集
- Smilow Cancer Center at Yale New Haven Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20007
- 募集
- Georgetown University Hospital
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- 募集
- University of Florida, Davis Cancer Center
-
Lake Mary、Florida、アメリカ、32746
- 終了しました
- Florida Cancer Specialist
-
Sarasota、Florida、アメリカ、34232-6422
- 募集
- Florida Cancer Specialists & Research Institute Sarasota
-
-
Kansas
-
Westwood、Kansas、アメリカ、66205
- 募集
- University of Kansas Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Beth Israel Deaconess Medical Center
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana Farber Cancer Institute
-
-
Michigan
-
Ypsilanti、Michigan、アメリカ、48197
- 募集
- Trinity Health Ann Arbor Hospital
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- 募集
- Hackensack University Medical Center
-
-
New York
-
Buffalo、New York、アメリカ、14263
- 募集
- Roswell Park Cancer Institute
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center
-
New York、New York、アメリカ、10032
- 終了しました
- Columbia University - Herbert Irving Comprehensive Cancer Center
-
Rochester、New York、アメリカ、14642
- 募集
- University of Rochester Medical Center James P. Wilmot Cancer Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- 募集
- Case Western
-
Maumee、Ohio、アメリカ、43537
- 募集
- Taylor Cancer Research Center
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- 募集
- Oregon Health and Science University
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University Medical Center
-
Nashville、Tennessee、アメリカ、37203
- 終了しました
- SCRI Oncology Partners
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- 募集
- NEXT Oncology
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- NEXT Oncology - Virginia Cancer Specialists
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- 募集
- University of Wisconsin Hospital
-
-
-
-
-
A Coruña、スペイン
- 募集
- Site ES34009
-
Barcelona、スペイン
- 募集
- Site ES34001
-
Barcelona、スペイン
- 募集
- Site ES34008
-
Barcelona、スペイン
- 募集
- Site ES34005
-
Madrid、スペイン
- 募集
- Site ES34004
-
Madrid、スペイン
- 募集
- Site ES34007
-
Madrid、スペイン
- 募集
- Site ES34006
-
Málaga、スペイン
- 募集
- Site ES34002
-
Seville、スペイン
- 募集
- Site ES34003
-
Valencia、スペイン
- 募集
- Site ES34010
-
-
Navarre
-
Pamplona、Navarre、スペイン
- 募集
- Site ES34011
-
-
-
-
-
Bordeaux、フランス
- 募集
- Site FR33002
-
Lyon、フランス
- 募集
- Site FR33001
-
Lyon、フランス
- 募集
- Site FR33005
-
-
Grenobele
-
La Tronche、Grenobele、フランス
- 募集
- Site FR33003
-
-
Île-de-France Region
-
Villejuif、Île-de-France Region、フランス
- 募集
- Site FR33004
-
-
-
-
-
San Juan、プエルトリコ、00935
- 募集
- PanOncology Trials
-
-
-
-
-
Shanghai、中国
- 募集
- Shanghai Pulmonary Hospital
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国
- 募集
- Beijing Cancer Hospital
-
-
Shanghai Municipality
-
Xuhui District、Shanghai Municipality、中国
- 募集
- Fudan University Shanghai Cancer Center
-
-
-
-
-
Osaka、日本
- 募集
- Osaka International Cancer Institute
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本
- 募集
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa、Chiba、日本
- 募集
- National Cancer Center Hospital East
-
-
Ehime
-
Matsuyama、Ehime、日本
- 募集
- Shikoku Cancer Center
-
-
Fukuoka
-
Kurume、Fukuoka、日本
- 募集
- Kurume University Hospital
-
-
Hokkaido
-
Sapporo、Hokkaido、日本
- 募集
- Hokkaido University Hospital
-
-
Kanagawa
-
Yokohama、Kanagawa、日本
- 募集
- Kanagawa Cancer Center
-
-
Miyagi
-
Sendai、Miyagi、日本
- 募集
- Tohoku University Hospital
-
-
Niigata
-
Niigata、Niigata、日本
- 募集
- Niigata Cancer Center Hospital
-
-
Osaka
-
Hirakata、Osaka、日本
- 募集
- Kansai Medical University Hospital
-
Sayama、Osaka、日本
- 募集
- Kindai University Hospital
-
-
Shizuoka
-
Sunto-gun、Shizuoka、日本
- 募集
- Shizuoka Cancer Center
-
-
Tokyo
-
Chuo-ku、Tokyo、日本
- 終了しました
- National Cancer Center Hospital
-
Koto-ku、Tokyo、日本
- 募集
- Cancer Institute Hospital of JFCR
-
-
Yamaguchi
-
Ube、Yamaguchi、日本
- 募集
- Yamaguchi University Hospital
-
-
-
-
-
Seoul、韓国
- 募集
- Site KR82006
-
-
Gyeonggi-do
-
Goyang-si、Gyeonggi-do、韓国
- 募集
- Site KR82005
-
Seongnam-si、Gyeonggi-do、韓国
- 募集
- Site KR82002
-
-
North Chungcheong
-
Cheongju-si、North Chungcheong、韓国
- 募集
- Site KR82007
-
-
Seoul
-
Jongno -Gu、Seoul、韓国
- 募集
- Site KR82001
-
Seodaemun-gu、Seoul、韓国
- 募集
- Site KR82003
-
Songpa-gu、Seoul、韓国
- 募集
- Site KR82004
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participant has locally advanced (unresectable) or metastatic solid tumor malignancy with documented Kirsten rat sarcoma viral oncogene homolog [KRAS] G12D mutation and has received prior standard therapy and the investigator does not see any further clinical benefit from continuing such targeted therapy, or is ineligible to receive standard approved therapies (no limit to the number of prior treatment regimens).
-
For the ASP3082 monotherapy escalation cohorts, participants with solid tumor malignancies are allowed to be enrolled. Participants with other known KRAS G12 mutations will not be eligible for the study
-
For ASP3082 combination therapy with Nab-P+GEM or FOLFIRINOX or NALRIFOX: Participant must have mPDAC that has not been previously treated with chemotherapy. If a participant received (neo)adjuvant therapy, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of the (neo)adjuvant therapy.
-
Participant consents to provide tumor specimen in a tissue block or unstained serial slides or a tumor biopsy (core needle biopsy or excision) obtained after the last interventional treatment, but prior to start of study intervention. Participant also consents to provide a sample for tumor biopsy during the treatment period as indicated in the study protocol. If a participant cannot provide a fresh tissue biopsy sample, the site should consult with the sponsor/study medical monitor.
-
Participant has at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
-
Participant has an ECOG performance status of 0, 1 or 2 for dose escalation, and 0 or 1 for dose expansion.
-
Participant's last dose of prior antineoplastic therapy, including any immunotherapy, was 21 days or 5 half-lives, whichever is shorter, prior to initiation of study intervention administration.
-
Participant has completed any radiotherapy (including stereotactic radiosurgery) at least 14 days prior to the start of study intervention administration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids (NOTE: Physiologic replacement dose of hydrocortisone or its equivalent [defined as up to 30 mg per day of hydrocortisone, 2 mg per day of dexamethasone, or up to 10 mg per day of prednisone] is permitted), and not have active radiation pneumonitis. A 1-week washout is permitted for palliative radiation (<= 2 weeks of radiotherapy) to non-central nervous system disease.
-
Participant's adverse events [AEs] (excluding alopecia) from prior therapy have improved to grade 1 or baseline within 14 days prior to start of study intervention (or prior to staring SoC chemotherapy, for first line (1L) participants receiving Nab-P+GEM FOLFIRINOX or NALIRIFOX.
-
Participant has adequate organ function as indicated by protocol laboratory value parameters (If a participant has received a recent blood transfusion, the laboratory tests must be obtained >= 14 days after any blood transfusion.).
-
Female participant is not pregnant, confirmed by pregnancy test and medical evaluation by interview, and at least 1 of the following conditions apply:
- Not a woman of childbearing potential (WOCBP).
- WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after study intervention administration.
- EU only: For combination therapy with carboplatin, follow contraception guidelines from the time of informed consent through at least 7 months after the final dose of carboplatin.
- South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 15 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 14 months after the final dose of cisplatin.
-
Female participant must agree not to breastfeed starting at screening and throughout the study period and for 6 months after study intervention administration.
-
Female participant must not donate ova starting at first dose of study intervention and throughout the study period and for 6 months after study intervention administration.
-
Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 3 months after study intervention administration.
-
Male participant must not donate sperm during the treatment period and for 3 months after study intervention administration.
-
South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 12 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 11 months after the final dose of cisplatin.
-
Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 3 months after study intervention administration.
-
Participant agrees not to participate in another interventional study while receiving study intervention (Participants who are currently in the follow-up period of an interventional clinical trial are allowed).
-
For ASP3082 Combination Therapy with Pembrolizumab (Cohort G), or Platinum-based Chemotherapy + Pemetrexed +/- Pembrolizumab (Cohort H): Participant must have pathologically documented locally advanced or metastatic (unresectable Stage IIIB-IV) non-small cell lung cancer (NSCLC) (Note: for Cohort H only, the tumor must be non-squamous NSCLC) with KRAS G12D mutation and
- have received prior platinum-containing chemotherapy (safety lead-in only) or
- have never received systemic therapy (up to 1 cycle of SoC pembrolizumab [defined as one 21-day cycle of 200 mg] in Cohort G and up to 1 cycle of SoC platinum-based chemotherapy ± pembrolizumab [defined as one 21-day cycle of 200 mg] or pembrolizumab [defined as one 21-day cycle of 200 mg] in Cohort H is permitted prior to Screening, provided a 21-day washout occurs before C1D1) for locally advanced or metastatic NSCLC with no oncogenic driver mutations. Participants who received adjuvant or neoadjuvant platinum-based chemotherapy and developed recurrent or metastatic disease more than 12 months after completing therapy may be enrolled.
Exclusion Criteria:
- Participant has received investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to start of study intervention.
- Participant has symptomatic or untreated central nervous system (CNS) metastases. Participants with asymptomatic, treated CNS metastases are eligible.
- Participant has leptomeningeal disease as a manifestation of the current malignancy.
- Participant has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed.
- Participant has a known or suspected hypersensitivity to ASP3082 or any components of the formulation used.
- Participant with active hepatitis B (including acute hepatitis B virus [HBV] or chronic HBV) or hepatitis C virus [HCV] (ribonucleic acid [RNA] detected by qualitative assay). HCV RNA testing is not required in participants with negative HCV antibody testing.
- Participant has a known history of human immunodeficiency virus [HIV] infection. No HIV testing is required unless mandated by a local health authority.
- Participant has had a myocardial infarction or unstable angina within 6 months prior to the start of study intervention, left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO) or currently has an uncontrolled illness including, but not limited to symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, obligate use of a cardiac pacemaker, or long QT syndrome.
- Participant has a corrected QT interval (single electrocardiogram [ECG]) using Fridericia's formula (QTcF) > 450 milliseconds (msec) (men) or >470 msec (women) during screening.
- Participant has received prior treatment with a specific KRAS G12D inhibitor/degrader or pan-RAS inhibitor/degrader targeting KRAS G12D. Participants who received prior treatment with a KRAS G12D inhibitor/degrader are eligible for the ASP3082 combination therapy cohort.
- Participant has an active infection requiring intravenous antibiotics within 14 days prior to study intervention.
- Participant is expected to require another form of antineoplastic therapy while on study treatment.
- Participant has any condition which makes the participant unsuitable for study participation (such as psychiatric illness/social situations that would limit compliance with study requirements).
- Participant has had major surgery within 4 weeks prior to first dose of study intervention.
For ASP3082 Combination Therapy:
- Prior discontinuation of cetuximab treatment due to toxicity or intolerance of cetuximab.
- History of interstitial lung disease requiring systemic steroid treatment. Note that a participant with resolved pulmonary infections or radiation pneumonitis is eligible.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ASP3082 Dose Escalation (Monotherapy Part 1)
Participants will receive ASP3082 in a 21-day cycle. |
Intravenous Infusion
他の名前:
|
|
実験的:ASP3082 Dose Expansion (Monotherapy Part 2)
Participants will receive ASP3082 with dose level(s) selected from dose escalation (part 1) in a 21-day cycle. |
Intravenous Infusion
他の名前:
|
|
実験的:ASP3082 + Cetuximab Dose Escalation (Combination Therapy Part 1)
Participants will receive ASP3082 in a 21-day cycle. Cetuximab will be administered weekly. |
Intravenous Infusion
他の名前:
Intravenous Infusion |
|
実験的:ASP3082 + Cetuximab Dose Expansion (Combination Therapy Part 2)
Participants will receive ASP3082 or ASP3082 + Cetuximab with dose level(s) selected from dose escalation (part 1) in a 21-day cycle. Cetuximab will be administered weekly. |
Intravenous Infusion
他の名前:
Intravenous Infusion |
|
実験的:ASP3082 China Safety Cohort
Participants will receive ASP3082 with dose level selected from dose escalation (Monotherapy part 1) in a 21-day cycle. |
Intravenous Infusion
他の名前:
|
|
実験的:Treatment naive PDAC cohort ASP3082 + FOLFIRINOX
Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with FOLFIRINOX (leucovorin [LV]/fluorouracil [5-FU]/irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle. |
Intravenous Infusion
他の名前:
Intravenous Infusion Intravenous Infusion Intravenous Infusion Intravenous Infusion |
|
実験的:Treatment naive PDAC cohort ASP3082 + Nab-Paclitaxel + Gemcitabine
Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with Nab-P + GEM (nanoparticle albumin-bound-paclitaxel plus gemcitabine) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle. |
Intravenous Infusion
他の名前:
Intravenous Infusion Intravenous Infusion |
|
実験的:ASP3082 + Docetaxel - NSCLC
Participants with KRAS G12D mutant will receive ASP3082 in combination with docetaxel in a 21-day cycle. |
Intravenous Infusion
他の名前:
Intravenous Infusion |
|
実験的:ASP3082 + Pembrolizumab - NSCLC
Participants with KRAS G12D mutant will receive ASP3082 in combination with pembrolizumab in a 21-day cycle. |
Intravenous Infusion
他の名前:
Intravenous Infusion |
|
実験的:ASP3082 + (Cisplatin or Carboplatin) and Pemetrexed +/- Pembrolizumab - NSCLC
Participants with KRAS G12D mutant will receive ASP3082 in combination with platinum-based chemotherapy (cisplatin or carboplatin) and pemetrexed, with or without pembrolizumab in a 21-day cycle. |
Intravenous Infusion
他の名前:
Intravenous Infusion Intravenous Infusion Intravenous Infusion Intravenous Infusion |
|
実験的:Treatment naive PDAC cohort ASP3082 + NALIRIFOX
Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with NALIRIFOX (leucovorin[LV]/fluorouracil[5-FU]/liposomal irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle. |
Intravenous Infusion
他の名前:
Intravenous Infusion Intravenous Infusion Intravenous Infusion Intravenous Infusion |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLTs)
時間枠:Up to 28 Days
|
A DLT is defined as any event meeting the DLT criteria excluding toxicities clearly related to disease progression or intercurrent illness or standard of care (SoC) regimens as determined by the investigator. |
Up to 28 Days
|
|
Number of Participants with Adverse Events (AEs)
時間枠:Up to 48 months
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study IP, whether or not considered related to the study investigational product (IP). Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study IP. This includes events related to the comparator and events related to the (study) procedures. |
Up to 48 months
|
|
Number of Participants with Serious Adverse Events (SAEs)
時間枠:Up to 48 months
|
An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other medically important events. |
Up to 48 months
|
|
Number of Participants with laboratory value abnormalities and/or adverse events (AEs)
時間枠:Up to 48 months
|
Number of participants with potentially clinically significant laboratory values. |
Up to 48 months
|
|
Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)
時間枠:Up to 48 months
|
Number of participants with potentially clinically significant ECG values. |
Up to 48 months
|
|
Number of Participants with vital sign abnormalities and/or adverse events (AEs)
時間枠:Up to 48 months
|
Number of participants with potentially clinically significant vital sign values. |
Up to 48 months
|
|
Number of Participants with physical exam abnormalities and/or adverse events
時間枠:Up to 48 months
|
Number of participants with potentially clinically significant physical exam values. |
Up to 48 months
|
|
Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status
時間枠:Up to 48 months
|
The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance. |
Up to 48 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
時間枠:Up to 48 months
|
ORR is defined as the proportion of participants whose best overall response is rated as complete response (CR) or partial response (PR) per RECIST v1.1. |
Up to 48 months
|
|
Duration of Response (DOR) per RECIST v 1.1
時間枠:Up to 48 months
|
DOR is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date of documented radiological disease progression per RECIST v1.1 or death in the absence of progression. |
Up to 48 months
|
|
Disease Control Rate (DCR) per RECIST v 1.1
時間枠:Up to 48 months
|
DCR is defined as the proportion of participants whose best overall response is rated as CR, PR or SD based on RECIST v1.1. |
Up to 48 months
|
|
Pharmacokinetics (PK) of ASP3082 in plasma: Area under the concentration-time curve (AUC)
時間枠:Up to 48 months
|
AUC will be recorded from the PK plasma samples collected. |
Up to 48 months
|
|
PK of ASP3082 in plasma: Maximum Concentration (Cmax)
時間枠:Up to 48 months
|
Cmax will be recorded from the PK plasma samples collected. |
Up to 48 months
|
|
PK of ASP3082 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)
時間枠:Up to 48 months
|
Ctrough will be recorded from the PK plasma samples collected. |
Up to 48 months
|
|
PK of ASP3082 in plasma: Time of maximum concentration (tmax)
時間枠:Up to 48 months
|
tmax will be recorded from the PK plasma samples collected. |
Up to 48 months
|
|
Changes in Kirsten rat sarcoma (KRAS) viral oncogene homolog G12D in tumor samples
時間枠:Up to 48 months
|
Changes in KRAS G12D in tumor samples will be measured. |
Up to 48 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Medical Director、Astellas Pharma Inc
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 病理学的プロセス
- 腫瘍性プロセス
- 病理学的状態、徴候および症状
- 新生物
- 新生物転移
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- カムプトテシン
- アルカロイド
- 酵素と補酵素
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 無機化学物質
- 塩素化合物
- 窒素化合物
- 調整錯体
- グアニン
- ヒポキサンチン
- ピリノン
- プリン
- グルタミン酸
- アミノ酸、酸性
- アミノ酸
- アミノ酸、ジカルボン酸
- タキソイド
- シクロデカン
- Diterpenes
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ヘルスケアの経済学と組織
- ホルミルテトラヒドロフォレート
- テトラヒドロフォレート
- 葉酸
- 羽毛
- プテリジン
- ウラシル
- ピリミジノン
- コエンザイム
- プラチナ化合物
- 経済
- ドセタキセル
- オキサリプラチン
- イリノテカン
- ペメトレキセド
- セツキシマブ
- ゲムシタビン
- フルオロウラシル
- カルボプラチン
- ロイコボリン
- シスプラチン
- ペンブロリズマブ
- イリノテカンsucrosofate
- 税金
その他の研究ID番号
- 3082-CL-0101
- jRCT2031220738 (レジストリ識別子:jRCT)
- CTR20250465 (レジストリ識別子:chinaDrugTrials.org.cn)
- 2022-501590-39-00 (レジストリ識別子:CTIS (EU))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
IPD 共有時間枠
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD 共有アクセス基準
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。